The value of a positron emission tomography and X-ray computed tomography (PET/CT) combined service in terms of diagnostic accuracy, cost-effectiveness and impact on clinical decision-making is welldocumented in the literature. Its role in the management of patients presenting with cancer is shifting from early staging and restaging to the early assessment of the treatment response. Currently, the application of PET/CT has extended to non-oncological specialties-mainly neurology, cardiology and rheumatology. A further emerging application for PET/CT is the imaging of infection/inflammation. This article illustrates some of the PET/CT applications in both oncological and non-oncological disorders. In view of the absence of this modality in Oman, this article aims to increase the awareness of the importance of these imaging modalities and their significant impact on diagnosis and management in both oncological and non-oncological specialties for patients of all age groups as well as the decision-makers.
The Medical Case for a Positron Emission
Tomography and X-ray Computed Tomography Combined Service in Oman *Naima K. Al-Bulushi, 1 Decree that stated that all Omani citizens shall get free of charge health services. Today, four decades later the Omani health sector has developed immensely. This is evidenced by the increases in the number of hospitals; the number of hospital beds; the purchasing of new equipment; the number, type and complexity of therapies; the technical proficiency of the staff, including those who are national, and the variety of procedures performed. Above all, the quality of the health service in the country has vastly improved. Four decades ago, there was only a very basic health service which provided, for instance, life-saving treatments only to those fortunate few who could reach a health centre or hospital. Nowadays highly complicated and skilled procedures and surgery are available to everyone. Currently, both those living in urban areas and those living in very remote areas can access the health services they need.
biggest recent additions to health services in the country. It included a well-equipped radiotherapy department with two linear accelerators, the first in the country. This meant that oncology patients no longer needed to travel to nearby countries for radiotherapy treatments. The NOC also includes departments of medical and paediatric oncology, haemato-oncology and nuclear medicine. However, an important contemporary key modality is missing in this centre and in the country as a whole: that of a PET/CT service. This article highlights the importance of PET/CT in managing cancer. By illustrating some of the applications of PET/CT, we hope to raise awareness of its importance and costeffectiveness.
Positron emission tomography (PET) was introduced in the 1970s as a research device in neurosciences and cardiology. Two decades later, X-ray computed tomography (CT) technology was added to the PET scanner, producing so-called fusion, or hybrid, imaging. A PET/CT combined scanner was first introduced in 1998. Since then, patients can be scanned both with PET and CT at the same time without having to move. The aim of this hybrid imaging was to combine the functional molecular imaging of PET with the high-contrast anatomical images provided by CT.
The value of combining PET and CT (PET/CT) in terms of diagnostic accuracy, cost-effectiveness and the impact on clinical decision-making and health outcomes are well-documented in the literature. 2 PET/CT imaging with the main radiopharmaceutical used, 18 F-fluorodeoxyglucose ( 18 F-FDG), is considered today, in most of the developed world, to be essential in the management of a range of malignancies. Table 1 lists the major malignancies or cancers where PET/CT provides a unique clinical value. In addition, the role of PET/ CT in the management of patients presenting with cancer is shifting from early staging and restaging after recurrence to the early assessment of treatment response. 3, 4 Currently, the use of 18 F-FDG PET/CT has extended to non-oncological applications as well. The main non-oncological use of 18 F-FDG PET is in neurology (mostly for diagnosing patients with dementia, or for localising the ictal focus in patients with drug-refractory epilepsy) and in cardiology (for assessing the myocardial viability F-FDG uptake in the region with reduced perfusion indicates myocardial viability, thus predicting that the patient will benefit from revascularisation procedures. On the other hand, a reduced 18 F-FDG uptake in the region, with reduced perfusion as well (i.e., matched perfusion/metabolic defects), indicates an irreversibly-damaged myocardium. 6 Of special interest to cardiology is a new agent for myocardial perfusion labelled with 18 F, the 18 F-BMS-747158-02, which is in an advanced stage of clinical validation.
As mentioned above, important non-oncological applications include neurological disorders, mainly to differentiate the various types of dementia. In addition, 18 F-FDG PET may have a role in the presurgical assessment of patients with partial complex seizures, where magnetic resonance imaging (MRI) is either normal or equivocal. 7 The use of 18 F-FDG in rheumatology has been documented, with applications including the assessment of disease activity in arthritis, based on evaluating the metabolic activity in synovitis; this parameter helps to measure disease activity in patients with rheumatoid arthritis. 8 Additionally, 18 F-FDG-PET is employed to evaluate the disease extent/activity in arteritis. 9 Recently, 18 F-FDG has also been used to evaluate the response to therapy, especially when using expensive biological drugs such as antitumour-necrosis factor (anti-TNF) drugs, as an early prediction of the clinical outcome reduces the overall cost of treatment. 10 An emerging use of PET/CT is to assess infection and inflammation. PET has both high sensitivity and specificity in imaging osteomyelitis. In addition, it has been used to evaluate sarcoidosis and inflammatory bowel disease.
11 Furthermore, 18 F-FDG PET/CT has an important role in evaluating patients with a fever of unknown origin (FUO), as it helps in the precise localisation and early identification of the underlying cause of this Future Uses of 18 
F-Labelled Radiotracers
Among the 4 short-lived cyclotron-produced PET isotopes, 18 F has the longest half-life (110 mins), making it the most suitable isotope to label PET radiotracers. It can be commercially produced, hence reducing the necessity of in-house cyclotron production in each PET/CT institute. This has resulted in a wide range of research projects worldwide to develop new 18 F-labelled PET radiotracers. One example of a newly developed PET radiotracer is 3'-deoxy-3'- In most patients with FUO, the main cause will turn out to be due to an infection, autoimmune disease or malignancy; using PET/CT as a single modality can diagnose and assess those diseases with a high level of sensitivity. 12 In spite of the wide range of applications mentioned above, however, the vast majority of clinical PET scans performed today worldwide are in the setting of cancer staging and restaging, in which PET/CT often 'upstages' many patients [ Figure 1 ]. 
With PET evaluation, the term "staging" refers to parameters N and M, since parameter T is best staged with morphological imaging such as computed tomography and/or magnetic resonance imaging. Furthermore, a common feature of positron emission tomography imaging with 18F-FDG is the prognostic information it provides, based on the intensity of uptake, as an indirect parameter of tumour aggressiveness.
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Sounding Board | 494 uptake detects cellular proliferation. 13 It shows a good uptake in a number of tumours: lung cancer, lymphoma, breast cancer and glioma. The sensitivity and specificity of FLT compared to that of FDG in those tumours is, however, beyond the scope of this article. Another 15 Another recently addition to the 18 F PET radiotracer family is 18 F-fluorocholine. This agent is used for imaging prostate cancer, where its main applications are to evaluate local recurrence or metastatic disease. It is being increasingly used in Europe and Japan [ Figure  2 ]. 16 Last but not least, is the radiotracer 18 F-sodium fluoride (NaF). It has been known for decades that 18 F-fluoride has a high affinity for bone, yet it was not widely used. This was mainly due to its high energy (511 Kilo-electron volts [keV]) which limited its use with the existing gamma cameras due to the scintillation employed-sodium iodide activated with thallium [NaI(Tl)]-being too low in density and of insufficient thickness, and hence having a low stopping power. Furthermore, Tc-methylene diphosphonate (MDP) was readily available and suitable for use with the gamma camera. Since the introduction of modern PET and PET/CT scanners, 18 F-fluoride has been more frequently used for evaluating bone abnormalities that are due to both benign and malignant diseases. There are a number of studies that have compared 99m Tc-MDP bone scanning to 18 F-fluoride PET and found that the latter has a higher diagnostic accuracy in detecting skeletal diseases. 17 PET Imaging Agents Other than 18 
F-Fluorodeoxyglucose
The use of 18 F-FDG suffers from important limitations in certain oncological conditions, due either to the physiological biodistribution (for instance, very high uptake in the brain cortex or at the excretion sites) that hampers identification of the tumour lesions, or to the low expression of the glucose transporter system in certain cancers (such as in prostate cancers, mucinous cancers, hepatocellular carcinomas and bronchioloalveolar lung cancers, among others). Alternative PET tracers can be employed in these conditions, for instance radiolabelled amino acids (such as tyrosine C-acetate is instead most frequently employed in patients with a hepatocellular carcinoma, another tumour characterised by the low expression of the glucose transporter proteins. Proximity with the very high uptake in the brain cortex can hamper the detection of primary brain tumours; in these patients, discrimination of tumour recurrence from post-radiotherapy scar/necrosis (which is not an easy task with conventional CT/MRI) is better achieved by using alternative PET tracers such as Ga-DOTA-TOC/NOC/ TATE). This radionuclide is especially attractive for PET centres since, despite its short physical half-life of only 68 mins, it is available even without an inhouse cyclotron as the product of a germanium- 18 F-fluorocholine positron emission tomography (PET)/X-ray computed tomography (CT) scan in a patient with prostatic adenocarcinoma. This imaging was done to assess the efficacy of therapy in this patient with a single bone metastasis, appearing one year after primary treatment (serum prostate-specific antigen was 2.4 ng/ml). The images are of the fused PET/CT transaxial section at the level of the femoral heads. A: The baseline images showed focal accumulation of the tracer in the left acetabulum, the only site of metastatic disease. B: The favorable response after external beam radiation therapy (EBRT) is shown in this image.
PET/CT should be introduced as soon as possible with a second one to follow. " 18 This was followed shortly with another expert mission in March 2010 which recommended: "A national PET/CT Scanner Centre including a cyclotron should be planned and built. The logical location for this would be the Royal Hospital as it has a large Oncology Program. " 19 This was shortly followed by another expert mission that took place in October 2010. In the feedback report the expert wrote: "The level of NM practice in Oman is of a remarkably high quality. The country looks very well prepared for PET. The medical doctors would only require a limited period of very focused training for PET practice. However, it would still require many of the other professionals needed to run a complex facility such as a cyclotron/ PET centre, namely radiopharmacists/chemists and medical physicists. Their preparation would be longer and training should start as soon as a positive decision is taken about the implementation of a cyclotron in the country. " 20 Two years later in 2012, the IAEA undertook an external audit of the practice of nuclear medicine in Oman. One of the recommendations of this expert mission was "consider introduction of PET/CT in the country. This will have positive return in the management of cancer patients and saving in the use of high cost chemotherapeutic drugs". 21 In the same year, another expert mission took place in September. It concluded: "There is a need for PET/ CT in Royal Hospital and Sultan Qaboos University Hospital (SQUH). Cyclotron facility in Muscat region is needed to supply radiopharmaceuticals for both centers. Such a project will take time and in view of the urgent need for PET/CT, exporting the radioactivity as a temporary solution should be considered. This is not cost-effective for long-term practice. The best option to establish such centre is to do it as a turnkey project. " 22 The last expert mission that took place at the time of writing this paper was in March 2013 and concluded: "There is an urgent need to (establish) two PET/CT scanners in Royal Hospital and SQUH, which is fully justified. There is also a need to establish a National Cyclotron Facility that can produce and supply the PET tracers to the local centers". 23 
How many Scanners are Needed to Provide Appropriate Access to PET/CT?
A detailed derivation of the population need is difficult to ascertain from the literature, but the most quoted current figures suggest that the appropriate number of PET scanners to provide adequate care for the population's clinical needs is approximately 1 per 1-1.5 million people, although the geographical spread of a nation's population may skew this. 24, 25 As the clinical utility and benefits to patient management of PET have been increasingly demonstrated in the most recent literature, even greater access to PET is likely in the future with a 20% annual growth rate of PET procedures expected after the year 2014. 26 In a recent review of PET access in Europe, it was recommended that one PET camera is needed per 1.2 million people to meet the population's needs, 24 and the report of the Department of Health in the UK recommended one camera per 1-1.5 million people. 25 The population number per PET scanner is much lower when it comes to the USA and other European countries, where there is one PET camera per 300,000-900,000 people [ Table 2]; 27 a similar distribution of PET cameras exists in some of the Gulf Cooperation Council (GCC) countries. 28 In the Australian PET report, the State Health Departments of Queensland and Victoria recommended 4 scanners in each state, hence assuming a ratio of one camera per 900,000 people and one camera per 1.2 million people, respectively. 29 However, Australia is not a densely populated country and by the end of 2012 there were 36 PET/CT cameras serving the population of 22.5 million. A more useful metric may be that for every one radiation therapy linear accelerator, a PET/CT camera is required.
Current Utilisation of PET/ CT Services in Oman
In Oman the importance of PET/CT imaging has been acknowledged for nearly a decade, especially for cancer patients. Due to the lack of PET/CT facilities in the country, patients are being sent abroad at the expense of the Ministry of Health.
Would PET/CT be a CostEffective Modality in Oman?
Reviewing the latest available cancer incidence statistics in Oman shows that there were 950 new cases diagnosed in 2010. 30 Additionally, the top 10 most common cancers in Oman are similar to the rest of the world. Breast cancer and cervical cancer represent the top two cancers in women, while prostate cancer is the top ranking cancer in men, followed by non-Hodgkin's lymphoma. 30 Bearing in mind the ideal utilisation of PET/CT imaging, there will be about 800-900 patients per year needing to be scanned for primary staging; about one-third of those patients will have early evaluations of the response to chemotherapy/radiotherapy by a second early scan, and later on a third scan will be needed to evaluate the response at completion of treatment. The above considerations will add to the current practice in Oman for cancer patients, who will benefit from restaging using PET/CT imaging; alternatively, as is currently the case, PET/CT can be used as a problem-solving tool when other investigations are inconclusive.
Using the above figure, it is calculated that more than 2,000 patients in departments of adult and paediatric oncology will benefit from PET/CT if it is available in the country. Also, it should be noted that these numbers were published two years ago and that there is an expected increase in the number of new cancer cases worldwide over the coming two decades, more so in developing countries. There will be an expected increase in the incidence of cancer cases from 12.7 million new cases in 2008 to 22.2 million cases in 2030. 31 This is further exacerbated in Oman by the rapidly increasing mean age of the population; more cancers are to be expected as the population lives longer. Furthermore, there are several instances in which patients with benign conditions will benefit from in-house PET/CT imaging, such as patients with coronary artery disease being evaluated for myocardial viability as well as patients with infectious diseases, and rheumatological and neurological conditions.
In the long term, it would be neither affordable nor cost-effective to send such a large number of patients abroad for PET/CT scans. Furthermore, the time factor in some of these cases is even more critical than the cost, especially for those patients The cases sent abroad are specially selected, and PET/CT is used in such cases as a problem-solving tool in cases where both the existing imaging modalities and the histopathology reports are inconclusive. Those patients are mainly from the medical oncology, haemato-oncology, paediatric oncology and endocrinology departments. Other medical specialties began sending patients with benign conditions for PET/CT imaging, primarily to evaluate viability in patients with coronary artery disease, or rheumatology patients (mainly those with vasculitis in whom the available imaging modalities, namely CT and MRI, were inconclusive).
So far, PET/CT imaging has not been fully utilised, particularly for oncology patients. Although experts in medical oncology and nuclear medicine realise the importance of using PET/CT in staging, mid-therapy evaluation, end-of-therapy evaluation, and restaging, they are not able to use PET/CT in this way. The fact that such a modality is not available in Oman places several important logistical limitations on the treatment options, as it is not cost-effective to send all of those patients abroad. who require re-evaluation half-way through treatment. In this regard, mid-treatment PET/CT scans to evaluate the response to chemotherapy have proven to be very useful for clinical decision-making regarding early changes in the treatment regimens [ Figure 3 ]. This approach helps in the efficient use of certain expensive chemotherapy drugs. For example, PET/CT imaging after 3 chemotherapy cycles in patients with non-Hodgkin lymphomas has helped save EUR 1,879 per patient in Belgium. 32 In this manner, PET/CT has the potential to enable personalised patient management. 5 This is the real future challenge for physicians in general, and not solely oncologists.
How many PET/CT Scanners and Cyclotrons are Needed in Oman?
The ratio of PET/CT scanners per population varies worldwide: the numbers vary from one scanner per population of 300,000 to one scanner per one million. At the time of writing, the population in Oman is approaching 3 million; hence, two PET/ CT scanners would be fully utilised, provided they were acquired soon. If, on the other hand, the approval/planning phase takes longer and 2-3 additional years are needed to begin building the facility (with an anticipated clinical introduction of 5 years), then 3 PET/CT scanners will be needed. This is due to both the increase in population and the number of newly diagnosed cancer cases, as well as the additional numbers of older cancer patients. Further delay in starting this project will only increase expenditure in the health sector, both by increasing the number of patients sent abroad for PET/CT and by the inappropriate usage of expensive, and potentially futile, chemotherapy.
The cyclotron, on the other hand, is a different issue. There is a need to install a national medium energy cyclotron. The two feasible options at present would be for the facility to be based either at the RH or SQUH. This cyclotron should be capable of producing all PET tracers for use within the same institutition and, additionally, 18 F-FDG or other 18 F-labelled radiotracers that can be transported to other PET/CT scanners located elsewhere. One of these facilities needs to be properly planned and then implemented immediately. Once it is fully functional, a second cyclotron could be planned for the other institute; in the long term, both the RH and SQUH need to have their own cyclotrons. This is because those two centres should be able to utilise PET/CT technology fully by using all radiotracers. Whereas It is envisaged that a minimum of 3 years is required to install a fully operational cyclotron, with this sometimes taking up to 5 years. One might ask if Oman should wait for the cyclotron before radiochemists) and technologists for the operation of the equipment is absolutely mandatory. Some of this should be undertaken abroad in facilities with PET experience and working practices similar to those in Oman.
• The education of referrers as to the appropriate use of PET imaging in the management of their patients is essential.
• Clear evidence-based guidelines should be developed as to the appropriate use of 18 F-FDG-PET scanning.
• A funding model should be developed, allowing for flexibility in addressing cancer issues of key importance in Oman. These may be slightly different to those in developed countries.
Conclusion
This article illustrates some of the applications of PET/CT in oncological and non-oncological patients. In view of the increase in the number of newly diagnosed cancer patients, in addition to the long-term follow-up needed for oncological patients in general, the demand for PET/CT will definitely increase in the future. It is important to consider that the number of new cancer patients mentioned is based on a Ministry of Health publication of new cancer cases registered in 2008. First, it should be noted that these figures do not include those patients who went abroad for diagnosis and/or treatment, either at private or government expense. Second, these numbers also do not include benign, non-oncological patients who received PET/CT scans abroad, either at government expense or privately sought second opinions. Therefore, if 2,000 oncological patients could have benefited from a PET/CT service 5 years ago and a further two years are required before PET/CT service will be available-assuming planning for such a service begins immediately-it is likely that, 7 years later, this number will definitively have doubled, if not tripled.
In conclusion, thousands of patients would benefit from an in-house PET/CT and cyclotron facility and thousands of Omani riyals would be saved in the long term. However, it important to remember that hypothetical calculations of the number of patients or money spent are easy, but the same is not true of calculations regarding the quality starting the PET/CT facility. The answer would be no; the best way to proceed would be to start planning for a comprehensive, integrated PET/CT and cyclotron facility. Installing a PET/CT scanner requires less time and it can be started in one to two years; until the cyclotron is functional, the scans can be perfomed using imported radiotracers, although in this case only 18 F-labelled tracers such as 18 F-FDG could be used. This will be a useful temporary solution until the cyclotron starts functioning. It would also provide a good back-up if the cyclotron has technical problems or needs maintenance. It is worth mentioning that importing 18 F-FDG should only be considered as a temporary solution. It will not be cost-effective in the long term and, additionally, will not allow the full utilisation of PET/CT.
Building the national capacity is desirable and should be established in parallel with the planning of the PET/CT and cyclotron facility. A team of highly trained and qualified staff is needed to run such a facility efficiently and safely. This team should include qualified medical physicists, radiochemists, radiopharmacists and nuclear medicine technologists.
Planning for the Future in Oman
Any Omani PET/CT initiative should address these key issues prior to introducing a local service:
• A long-term plan is needed to consider the number of PET/CT scanners required, the location of the facilities and a possible timeline for their introduction.
• A consideration of the need for a cyclotron within Oman versus a supply of radiotracers from other GCC states should be undertaken. Even with an internal source of positron-emitting tracers, consideration should be given to external backup facilities to allow for continued service during scheduled maintenance and unexpected outages.
• Taking into consideration the complexity of such facilities and international requirements, particularly the Good Manufacturing Practice (GMP) guidelines, a turnkey project would be the best option for building such facilities.
• The education and training of physicians/ radiologists, scientists (physicists and of the service. In a country like Oman, where there have been tremendous improvements in the health services over the last four decades, and where there is good will towards further improvement, it is the authors' opinions that PET/CT is no longer an option, but a necessity.
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